Fulcrum Therapeutics, Inc. - Common Stock (FULC)
CUSIP: 359616109
Q3 2024 13F Holders as of 30 Sep 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 67,171,444
- Total 13F shares
- 54,857,560
- Share change
- -10,802,889
- Total reported value
- $195,845,950
- Put/Call ratio
- 26%
- Price per share
- $3.57
- Number of holders
- 127
- Value change
- -$86,380,213
- Number of buys
- 72
- Number of sells
- 70
Quarterly Holders Quick Answers
What is CUSIP 359616109?
CUSIP 359616109 identifies FULC - Fulcrum Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 359616109:
Top shareholders of FULC - Fulcrum Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
17%
|
11,609,704
|
$71,980,165 | — | 30 Jun 2024 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
8.7%
|
5,845,956
|
$36,244,927 | — | 30 Jun 2024 | |
| FMR LLC |
13F
|
Company |
7.9%
|
5,329,946
|
$33,045,666 | — | 30 Jun 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
7.1%
|
4,798,522
|
$29,750,836 | — | 30 Jun 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.6%
|
3,071,143
|
$19,041,086 | — | 30 Jun 2024 | |
| COWEN AND COMPANY, LLC |
13F
|
Company |
4.4%
|
2,964,127
|
$18,377,586 | — | 30 Jun 2024 | |
| Nantahala Capital Management, LLC |
13D/G
|
— |
7.7%
|
4,777,912
|
$17,439,379 | $0 | 30 Sep 2024 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
3.8%
|
2,541,046
|
$15,754,485 | — | 30 Jun 2024 | |
| TRV GP IV, LLC |
13F
|
Company |
3.5%
|
2,343,154
|
$14,527,555 | — | 30 Jun 2024 | |
| Third Rock Ventures III, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,305,356
|
$14,250,729 | — | 13 Dec 2022 | |
| Mark J. Levin |
3/4/5
|
Director, 10%+ Owner |
—
class O/S missing
|
4,038,002
|
$13,365,787 | — | 10 Nov 2021 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.6%
|
1,777,112
|
$11,018,095 | — | 30 Jun 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
2.2%
|
1,480,926
|
$9,182,168 | — | 30 Jun 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
2.2%
|
1,444,851
|
$8,958,076 | — | 30 Jun 2024 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
2.1%
|
1,433,316
|
$8,886,559 | — | 30 Jun 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.9%
|
1,307,377
|
$8,107,443 | — | 30 Jun 2024 | |
| MORGAN STANLEY |
13F
|
Company |
1.8%
|
1,234,813
|
$7,655,841 | — | 30 Jun 2024 | |
| Vestal Point Capital, LP |
13F
|
Company |
1.7%
|
1,160,000
|
$7,192,000 | — | 30 Jun 2024 | |
| STATE STREET CORP |
13F
|
Company |
1.6%
|
1,041,274
|
$6,455,899 | — | 30 Jun 2024 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
1.3%
|
849,193
|
$5,264,997 | — | 30 Jun 2024 | |
| Propel Bio Management, LLC |
13F
|
Company |
1.1%
|
750,000
|
$4,650,000 | — | 30 Jun 2024 | |
| Rock Springs Capital Management LP |
13F
|
Company |
1.1%
|
727,673
|
$4,511,573 | — | 30 Jun 2024 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
1%
|
696,464
|
$4,318,077 | — | 30 Jun 2024 | |
| Simplify Asset Management Inc. |
13F
|
Company |
1%
|
674,832
|
$4,183,958 | — | 30 Jun 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.88%
|
591,785
|
$3,669,067 | — | 30 Jun 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.84%
|
563,500
|
$3,493,700 | — | 30 Jun 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.83%
|
560,492
|
$3,475,050 | — | 30 Jun 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.82%
|
553,307
|
$3,430,504 | — | 30 Jun 2024 | |
| Caption Management, LLC |
13F
|
Company |
0.78%
|
525,300
|
$3,256,860 | — | 30 Jun 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.76%
|
509,688
|
$3,160,066 | — | 30 Jun 2024 | |
| Woodline Partners LP |
13F
|
Company |
0.75%
|
501,301
|
$3,108,066 | — | 30 Jun 2024 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.74%
|
497,456
|
$3,084,227 | — | 30 Jun 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.6%
|
402,749
|
$2,497,044 | — | 30 Jun 2024 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.59%
|
398,436
|
$2,470,303 | — | 30 Jun 2024 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
0.55%
|
368,369
|
$2,283,888 | — | 30 Jun 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.5%
|
333,161
|
$2,065,598 | — | 30 Jun 2024 | |
| Exome Asset Management LLC |
13F
|
Company |
0.45%
|
302,700
|
$1,876,740 | — | 30 Jun 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.45%
|
300,000
|
$1,860,000 | — | 30 Jun 2024 | |
| BESSEMER GROUP INC |
13F
|
Company |
0.43%
|
286,988
|
$1,779,000 | — | 30 Jun 2024 | |
| Opaleye Management Inc. |
13F
|
Company |
0.42%
|
285,000
|
$1,767,000 | — | 30 Jun 2024 | |
| Aberdeen Group plc |
13F
|
Company |
0.38%
|
256,888
|
$1,592,706 | — | 30 Jun 2024 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.33%
|
222,982
|
$1,382,488 | — | 30 Jun 2024 | |
| Mass General Brigham, Inc |
13F
|
Company |
0.31%
|
205,356
|
$1,273,207 | — | 30 Jun 2024 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
0.3%
|
202,148
|
$1,253,318 | — | 30 Jun 2024 | |
| UBS Group AG |
13F
|
Company |
0.28%
|
190,551
|
$1,181,416 | — | 30 Jun 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.28%
|
186,727
|
$1,157,707 | — | 30 Jun 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.27%
|
182,729
|
$1,132,920 | — | 30 Jun 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.26%
|
175,983
|
$1,091,095 | — | 30 Jun 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.25%
|
169,549
|
$1,051,204 | — | 30 Jun 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.25%
|
168,244
|
$1,043,113 | — | 30 Jun 2024 |
Institutional Holders of Fulcrum Therapeutics, Inc. - Common Stock (FULC) as of Q3 2024
As of 30 Sep 2024,
Fulcrum Therapeutics, Inc. - Common Stock (FULC) was held by
127 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
54,857,560 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., BlackRock, Inc., TCG Crossover Management, LLC, Nantahala Capital Management, LLC, VANGUARD GROUP INC, TRV GP IV, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., FMR LLC, STATE STREET CORP, and DIMENSIONAL FUND ADVISORS LP.
This page lists
127
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
120
Q3 2024 holders
127
Holder diff
7
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 Value $ | Q3 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.